Related Experiment Video
Updated: May 19, 2026
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
HLA and non-HLA polymorphisms in renal transplantation
Stéphanie Laperrousaz1, Stéphanie Tiercy, Jean Villard
1Transplant Immunology Unit and Swiss National Reference Laboratory for Histocompatibility (LNRH), Geneva University Hospital and Medical School, Geneva, Switzerland. sylvie.ferrari[at]hcuge.ch
Swiss Medical Weekly
|September 1, 2012
Summary
Human leukocyte antigen (HLA) compatibility is crucial for kidney transplant success. While natural killer (NK) cell and cytokine genetics may play roles, their clinical impact requires further research before use in organ allocation.
Area of Science:
- Immunogenetics
- Transplantation immunology
Background:
- Graft rejection remains a significant challenge in solid organ transplantation, impacting patient morbidity and mortality.
- Human leukocyte antigen (HLA) compatibility between donor and recipient is a primary determinant of renal transplant success, despite advancements in immunosuppression.
- Natural killer (NK) cell alloreactivity and cytokine genetic polymorphisms are implicated in transplant immune responses, but their precise roles are debated.
Purpose of the Study:
- To evaluate the significance of HLA compatibility, KIR-HLA interactions, and cytokine gene polymorphisms in renal transplantation outcomes.
- To determine if KIR gene and cytokine genetic variations can be used as prognostic factors or for organ allocation criteria.
Main Methods:
- The study likely involved analyzing genetic data (HLA, KIR genes, cytokine polymorphisms) from donors and recipients.
- Correlation analysis between genetic profiles and renal transplant outcomes (e.g., graft survival, rejection episodes) was probably performed.
Main Results:
- HLA compatibility at specific loci (HLA-A, HLA-B, HLA-DR) remains a critical factor for successful renal transplantation.
- The clinical impact of combined KIR gene and HLA ligand interactions is not yet clearly established.
- The role of genetic polymorphisms in cytokines in influencing transplant outcomes is still under debate.
Conclusions:
- HLA compatibility is essential for renal transplantation and should remain a primary consideration.
- It is premature to utilize KIR gene and cytokine genetic variations as criteria for organ allocation or as definitive prognostic factors in renal transplantation.
Related Concept Videos
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:24Tissue Transplantation
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...